Advancing vaccine development to help all people live longer, healthier lives
Are you attending the Global Forum on TB Vaccines? "Stop" by our booth or schedule a meeting with one of our team.
CLAUDIA CHRISTIAN
Senior Vice President
Clinical Operations
We envision a world where advances in vaccines and medicines help all people live longer, healthier lives.
We offer a unique combination of in-country technical, regulatory and cultural knowledge and an established global presence in Africa, Asia, Europe, Latin America and North America.
We adapt our processes and workflow as your study needs change. No matter how large or small the project, we remain agile and exact, because your research demands it.
We have research at our core. A subsidiary of FHI 360, we benefit from our parent company’s 50+ year history of clinical research and success in creating and growing CROs.
Our mission is to address unmet research needs and achieve maximum social impact by supporting the development of life-saving vaccines and medicines.
Let us help you enter hard-to-reach markets and access the right patient populations.
Tailored services to meet your needs, from protocol design and site assessments to trial planning, implementation and management.
Ability to address challenges across dozens of therapeutic areas, including infectious diseases (IDs), neglected tropical diseases (NTDs), emerging and reemerging diseases, and pediatric studies.
Leverage established partnerships with leading public and private medical research organizations, pharmaceutical and biotechnology companies, academic institutions, the U.S. National Institutes of Health (NIH), the U.S. Centers for Disease Control and Prevention (CDC) and the U.S. Agency for International Development (USAID).
As we monitor the rapidly changing COVID-19 situation, reliable data sources are crucial. We recommend this resource from Johns Hopkins University to better understand the pandemic’s impact.
The data sources include the World Health Organization, the U.S. Centers for Disease Control and Prevention, the European Center for Disease Prevention and Control, the National Health Commission of the People’s Republic of China, 1point3acres, Worldometers.info, BNO, state and national government health departments, local media reports, and the DXY, one of the world’s largest online communities for physicians, health care professionals, pharmacies and facilities.
Results of the Adaptive COVID-19 Treatment Trial (ACTT)-2 investigating combination treatment with baricitinib, a Janus kinase inhibitor, and remdesivir for the treatment of COVID-19 in hospitalized adults were published in the New England Journal of Medicine (NEJM) on March 4, 2021, showing that the combination treatment was superior to remdesivir alone.
April 29, 2021
Biomedical researchers, clinical research organizations, people infected and impacted by the pandemic, along with Black barbers and stylists, will come together in a virtual event April 29 at 6 p.m. to provide straight talk about fears, trust issues, and why we need our Black and Brown community to be part of COVID-19 vaccine research.
To debunk some myths around COVID-19 and the vaccine, a powerhouse panel of distinguished physicians, public health professionals and other leaders had a frank video discussion about the effects of COVID-19 on Black and brown communities.
FHI Clinical Headquarters
359 Blackwell Street, Suite 200
Durham, NC 27701 USA